Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. related to alleged violations of federal securities laws during the Phase 3 PALISADE-3 trial of fasedienol, a treatment for social anxiety disorder [4]. Group 1: Legal Investigation - The law firm is encouraging Vistagen investors who suffered losses exceeding $50,000 to contact them for discussing legal options [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Vistagen and its executives made false or misleading statements and failed to disclose material adverse facts regarding their clinical trial [4]. Group 2: Firm Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3]. - The firm has offices in New York, Pennsylvania, California, and Georgia, indicating a broad operational footprint [3]. Group 3: Whistleblower Encouragement - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [6].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly making false and misleading statements regarding its business and the development of its drug fasedienol during the Class Period from April 1, 2024, to December 16, 2025 [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors under federal securities laws for those who purchased Vistagen securities during the specified Class Period [1]. - Investors have until March 16, 2026, to seek appointment as lead plaintiff if they suffered losses [2]. Group 2: Allegations Against Vistagen - The complaint alleges that Vistagen's defendants provided overly positive statements about the development and prospects of fasedienol, despite adverse facts related to the Phase 3 PALISADE-3 clinical trial for social anxiety disorder [3]. - It is claimed that the defendants failed to disclose material adverse data concerning the study's design, execution, and clinical results, leading to materially false and misleading statements about the company's business and operations [3]. Group 3: Law Firm Background - Johnson Fistel, PLLP is a recognized shareholder rights law firm that represents individual and institutional investors in securities class actions, with a notable recovery of approximately $90.7 million for investors in 2024 [4].

Core Viewpoint - The complaint alleges that Vistagen Therapeutics and its executives violated federal securities laws by making false or misleading statements and failing to disclose material adverse facts regarding its Phase 3 PALISADE-3 trial study of fasedienol, which is being developed for the acute treatment of social anxiety disorder [2] Group 1 - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class, who directs and oversees the litigation on behalf of the putative class [3] - Any member of the putative class may move the Court to serve as lead plaintiff or may choose to remain an absent class member without affecting their ability to share in any recovery [3] Group 2 - Faruqi & Faruqi, LLP encourages anyone with information regarding Vistagen's conduct to contact the firm, including whistleblowers, former employees, and shareholders [4]

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its Phase 3 PALISADE-3 trial of fasedienol, which did not meet its primary endpoint, leading to a significant decline in stock price [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between April 1, 2024, and December 16, 2025 [1]. - Defendants allegedly made positive statements while concealing adverse facts about the Phase 3 PALISADE-3 trial of fasedienol, which is intended for treating social anxiety disorder [2]. - Following the announcement that the trial did not show statistically significant improvement, Vistagen's stock price plummeted from $4.36 to $0.86, a decline of over 80% [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until March 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions for shareholders and being recognized as a top securities litigation firm in the U.S. for seven consecutive years [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Vistagen Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Vistagen common stock between April 1, 2024, and December 16, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 16, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [7]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized for its success in the field [4]. Group 3: Case Background - The lawsuit alleges that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder, while concealing material adverse facts about its Phase 3 PALISADE-3 trial [5][6]. - The defendants' positive assertions about the drug's trial success were contradicted by undisclosed negative information, leading to investor damages when the truth emerged [6].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Vistagen Therapeutics, Inc. on behalf of investors who purchased or acquired the company's common stock between April 1, 2024, and December 16, 2025, alleging misrepresentations related to the company's clinical trial [1][4]. Group 1: Lawsuit Details - The lawsuit claims that the defendants made misrepresentations concerning the Company's Phase 3 PALISADE-3 trial study of fasedienol, which is an investigational pherine candidate for the acute treatment of social anxiety disorder [4]. - Investors who wish to serve as lead plaintiff must file papers by March 16, 2026, and participation as a lead plaintiff is not required to share in any recovery [3]. Group 2: Legal Representation - Bernstein Liebhard LLP, the law firm handling the case, has recovered over $3.5 billion for its clients since 1993 and has a strong track record in class action litigation [5].

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its Phase 3 PALISADE-3 trial of fasedienol, which did not meet its primary endpoint, leading to a significant stock price decline of over 80% [1][2]. Group 1: Allegations and Trial Results - The lawsuit claims that Vistagen provided overly positive statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder [1]. - On December 17, 2025, Vistagen announced that the PALISADE-3 trial did not show a statistically significant improvement on the primary endpoint, with no treatment difference between fasedienol and placebo for secondary endpoints [1]. - Following the announcement, Vistagen's stock price plummeted from $4.36 per share on December 16, 2025, to $0.86 per share on December 17, 2025, marking a decline of more than 80% [1]. Group 2: Class Action Details - Shareholders who purchased VTGN shares during the class period from April 1, 2024, to December 16, 2025, are encouraged to register for the class action, with a deadline of March 16, 2026, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case, with no cost or obligation to participate [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [3].

Core Viewpoint - A class action has been filed against Vistagen Therapeutics, Inc. for allegedly misleading investors regarding the viability of its Phase 3 trial study of fasedienol, leading to significant financial losses for shareholders [1][2]. Group 1: Class Action Details - The class action is on behalf of all investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025 [1][2]. - Allegations include that Vistagen provided misleading statements about the success of its Phase 3 PALISADE-3 trial for fasedienol while concealing adverse facts [2][3]. Group 2: Trial Results and Impact - On December 17, 2025, Vistagen announced that the PALISADE-3 trial did not show statistically significant improvement on its primary endpoint, leading to a dramatic stock price drop from $4.36 to $0.86, a decline of over 80% [3]. Group 3: Next Steps for Investors - Shareholders wishing to serve as lead plaintiffs must submit their papers by March 16, 2026, but participation is not required to be eligible for recovery [4].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options If you purchased or acquired Vistagen common stock between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Forunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- What’s Happening: ...

NEW YORK, Feb. 04, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Vistagen Therapeutics, Inc. (NASDAQ: VTGN). Shareholders who purchased shares of VTGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/vistagen-therapeutics-inc-loss-submission-form/?id=183336&from=3 CLASS ...